KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Assets (2016 - 2025)

Neogenomics' Assets history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Assets fell 16.98% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, down 16.98%, while the annual FY2025 figure was $1.4 billion, 16.98% down from the prior year.
  • Assets reached $1.4 billion in Q4 2025 per NEO's latest filing, down from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.9 billion in Q3 2021 to a low of $1.4 billion in Q4 2025.
  • Average Assets over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2023.
  • Peak YoY movement for Assets: surged 7379.11% in 2021, then decreased 16.98% in 2025.
  • A 5-year view of Assets shows it stood at $1.9 billion in 2021, then fell by 6.94% to $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NEO's Assets are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).